Latest Interviews
Showing 1–2 of 2 transcripts.
Clear all filters- a16z19 min
Healthcare Has Left the Building
A structural transformation is dissolving traditional silos between payers, providers, and technology firms to shift care from centralized hospitals to home settings while leveraging mobile diagnostics and AI-driven logistics. Major market entrants are challenging established models through value-based care initiatives and programmed therapies that enable proactive monitoring and personalized treatments like gene editing. This evolution modernizes the medical ecosystem to prioritize patient outcomes and efficiency, though the fundamental human need for care remains the driving force behind these technological accelerations.
- a16z59 min
a16z Podcast | The Science and Business of Innovative Medicines
Jorge Conde, Vijay Pande, Sonal Chokshi, Vas Narasimhan
Novartis transformed its portfolio through a $50 billion restructuring that divested consumer healthcare to prioritize advanced therapies, data science, and proprietary platforms for cell and gene treatments. Under CEO Vas Narasimhan, the company enforces strict "standard of care" mandates for project approval, integrates market access early in development, and invested $15 billion to own specialized infrastructure while leveraging AI for financial forecasting and pathology analysis. This strategic pivot targets a 10% clinical success rate by shifting from bespoke drug development to modular platforms and dedicated digital innovation centers, positioning the firm to address undruggable targets and future modalities like xenotransplantation.